Is Moderna (MRNA) Attractive After A 73% Year To Date Share Price Jump?

Simply Wall St.03-27

Wondering if Moderna at US$53.54 is a bargain or a value trap? This article walks through what the numbers are really saying about the stock. The share price return sits at 2.2% over 7 days, 6.5% over...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622895399?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/128680956-main-header/1756229826628","is_english":true,"pubTime":"2026-03-27 01:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622895399","market":"us","top_or_hot":-1,"title":"Is Moderna (MRNA) Attractive After A 73% Year To Date Share Price Jump?","media":"Simply Wall St.","content":"<div>\n<p>Wondering if Moderna at US$53.54 is a bargain or a value trap? This article walks through what the numbers are really saying about the stock. The share price return sits at 2.2% over 7 days, 6.5% over...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/is-moderna-mrna-attractive-after-a-73-year-to-date-share-pri\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Moderna (MRNA) Attractive After A 73% Year To Date Share Price Jump?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Moderna (MRNA) Attractive After A 73% Year To Date Share Price Jump?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-27 01:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/is-moderna-mrna-attractive-after-a-73-year-to-date-share-pri><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wondering if Moderna at US$53.54 is a bargain or a value trap? This article walks through what the numbers are really saying about the stock. The share price return sits at 2.2% over 7 days, 6.5% over...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/is-moderna-mrna-attractive-after-a-73-year-to-date-share-pri\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4551","symbol_name":"寇图资本持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/is-moderna-mrna-attractive-after-a-73-year-to-date-share-pri","article_id":"2622895399","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/128680956-main-header/1756229826628"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/is-moderna-mrna-attractive-after-a-73-year-to-date-share-pri","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2622895399","pubTimestamp":1774545313,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Wondering if Moderna at US$53.54 is a bargain or a value trap? This article walks through what the numbers are really saying about the stock.\nThe share price return sits at 2.2% over 7 days, 6.5% over 30 days, 73.5% year to date and 70.1% over the last year, alongside a 64.0% decline over 3 years and a 59.1% decline over 5 years.\nRecent headlines around Moderna have focused on its position in the pharmaceutical and biotech space and how investors are reassessing companies in this part of the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4551":"寇图资本持仓","BK4501":"段永平概念","MRNA":"Moderna, Inc.","BK4588":"碎股","BK4211":"区域性银行","BK4585":"ETF&股票定投概念","MRNY":"MRNA期权收益策略ETF-YieldMax","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","BK4534":"瑞士信贷持仓","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4139":"生物科技","FCF":"第一联邦金融","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4532":"文艺复兴科技持仓","MRNX":"Defiance Daily Target 2X Long MRNA ETF"},"translate_title":"Moderna(MRNA)股价今年迄今上涨73%后是否有吸引力？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"FCF":1,"MRNX":0.6,"MRNY":0.6,"MRNA":1.5},"content_text":"Wondering if Moderna at US$53.54 is a bargain or a value trap? This article walks through what the numbers are really saying about the stock. The share price return sits at 2.2% over 7 days, 6.5% over 30 days, 73.5% year to date and 70.1% over the last year, alongside a 64.0% decline over 3 years and a 59.1% decline over 5 years. Recent headlines around Moderna have focused on its position in the pharmaceutical and biotech space and how investors are reassessing companies in this part of the market. This shifting attention provides important context for the recent share price moves and why valuation has come back into focus for many investors. Despite all of this, Moderna currently records a valuation score of 0 out of 6. The next sections will break down what different valuation approaches suggest about the stock and then look at a more complete framework for thinking about value overall.  Moderna scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown. AdvertisementApproach 1: Moderna Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model estimates what a business could be worth by projecting its future cash flows and discounting them back to today using a required rate of return. It looks at the cash the company might generate for shareholders rather than just current earnings. For Moderna, the latest twelve month free cash flow (FCF) is a loss of about $2.19b. Analyst and extrapolated estimates used in this 2 Stage Free Cash Flow to Equity model suggest FCF remains negative for several years, then turns positive, reaching $254m in 2030. Further out, projections step up gradually into the mid hundreds of millions of dollars per year, all expressed in dollars and then discounted to today. Putting these cash flow projections together, the model arrives at an estimated intrinsic value of about $27.64 per share. Compared with the recent share price of US$53.54, the DCF output implies the stock is around 93.7% overvalued on this set of assumptions. Result: OVERVALUED Our Discounted Cash Flow (DCF) analysis suggests Moderna may be overvalued by 93.7%. Discover 55 high quality undervalued stocks or create your own screener to find better value opportunities. MRNA Discounted Cash Flow as at Mar 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Moderna. Approach 2: Moderna Price vs Sales For companies where earnings are limited or volatile, the P/S ratio is often more useful than P/E, because it compares the share price with the revenue being generated rather than current profits. Investors typically expect higher P/S multiples when they see stronger growth potential and lower perceived risk, and lower P/S multiples when growth expectations are softer or risks are higher. Moderna currently trades on a P/S of 10.92x. This is close to the broader Biotechs industry average P/S of 10.84x, and above the peer group average of 4.74x. Simply Wall St also calculates a proprietary “Fair Ratio” for the P/S multiple, which for Moderna is 1.34x. This Fair Ratio reflects factors such as earnings growth assumptions, profit margins, size, industry and specific risks, rather than relying only on simple peer or industry comparisons. Because the Fair Ratio of 1.34x is well below the current P/S of 10.92x, this framework suggests the shares trade at a richer level than would be implied by those fundamentals. Result: OVERVALUED NasdaqGS:MRNA P/S Ratio as at Mar 2026 P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies. Upgrade Your Decision Making: Choose your Moderna Narrative Earlier it was mentioned that there is an even better way to think about valuation, and on Simply Wall St that comes through Narratives, where you pick the story you believe about Moderna, link that story to clear forecasts, and then see a fair value you can compare with the current share price. Put simply, a Narrative is your explanation for what is really driving Moderna, combined with concrete numbers for future revenue, earnings and margins. Instead of just plugging figures into a model, you anchor those figures to a story you actually believe. Each Narrative on the Community page connects that story to a full forecast and a fair value estimate, then sets it alongside the live share price. This helps you decide whether the gap between price and value is big enough for you to consider buying, holding or selling. These Narratives update as new data and news arrive. When earnings, regulatory updates or clinical results shift the outlook, the fair value view moves with it rather than sitting frozen in time. For Moderna, one Community member currently assumes a fair value of about US$12 per share while another sees about US$175 per share. That wide range shows how different stories about mRNA demand, pricing pressure, litigation and the pipeline can lead to very different conclusions about what the stock is worth today. For Moderna however we will make it really easy for you with previews of two leading Moderna Narratives: 🐂 Moderna Bull Case Fair value in this Narrative: US$175.00 per share Implied discount to this fair value vs the latest close: about 69.4% undervalued Revenue growth used in this Narrative: 48.43%  Argues that Moderna used its COVID-19 windfall to build a large pipeline while keeping the balance sheet relatively clean and the shares trading near or below book value. Frames the sharp pullback from the pandemic share price peak as an overreaction during a transition period as pipeline projects progress through trials. Views Moderna as a comparatively lower risk biotech idea for value focused investors, with multiple shots on goal across existing and pipeline products.  🐻 Moderna Bear Case Fair value in this Narrative: US$38.80 per share Implied premium to this fair value vs the latest close: about 38.0% overvalued Revenue growth used in this Narrative: 11.47%  Sees the expanded mRNA pipeline and cost measures as helpful, but questions whether they fully offset slowing vaccine demand and competition. Highlights execution and policy risks, including pricing pressure, regulatory shifts and reliance on cost cuts and external partners to fund more expensive programs. Points out that the analyst fair value and required future P/E assume meaningful earnings progress and multiple support, which may be hard to justify if key products or trials disappoint.  If you want to keep tracking how these bullish and bearish stories evolve as new data comes through, the easiest next step is to check the full range of Community views and fair value work on Moderna. You can then decide which story comes closest to your own expectations for the business and the stock. Do you think there's more to the story for Moderna? Head over to our Community to see what others are saying! NasdaqGS:MRNA 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622895399","isCrawlerRequest":true}